Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Ghebremariam, Yohannes T ^a,b   Cooke, John P ^a   Gerhart, William ^c   Griego, Carol ^d   Brower, Jeremy B ^d   Doyle Eisele, Melanie ^d   Moeller, Benjamin C ^d   Zhou, Qingtao ^e   Ho, Lawrence ^f   de Andrade, Joao ^g   Raghu, Ganesh ^h   Peterson, Leif ^a   Rivera, Andreana ^a   Rosen, Glenn D ^f  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Altitude Pharmaceuticals Inc   (United States)

^d LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^e PEKING UNIVERSITY THIRD HOSPITAL   (China)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Fibrosis; Inflammation; Oxidative stress; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; FIBRONECTIN RECEPTOR; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; BLEOMYCIN; COLLAGEN; PROTON PUMP INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; RAT; RETROSPECTIVE STUDY; SURVIVAL TIME; AGED; ANIMAL; APOPTOSIS; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; CELL SEPARATION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; IONIZING RADIATION; LUNG; LUNG TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; PLEIOTROPY; RADIATION RESPONSE; SOLUBILITY; SURVIVAL ANALYSIS;

AGED; ANIMALS; APOPTOSIS; BIOMARKERS; BLEOMYCIN; CELL PROLIFERATION; CELL SEPARATION; COLLAGEN; DISEASE MODELS, ANIMAL; ESOMEPRAZOLE; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GENETIC PLEIOTROPY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMONIA; PROTON PUMP INHIBITORS; RADIATION, IONIZING; RATS, INBRED F344; SOLUBILITY; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84938094276     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0614-x     Document Type: Article

References (98)

1. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC et al (2014) Idiopathic pulmonary fibrosis in us medicare beneficiaries aged 65years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2:566-572
2. Hodgson U, Laitinen T, Tukiainen P (2002) Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in finland. Thorax 57:338-342
3. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ (2000) Adult familial cryptogenic fibrosing alveolitis in the united kingdom. Thorax 55:143-146
4. Nadrous HF, Myers JL, Decker PA, Ryu JH (2005) Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 80:37-40
5. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083-2092
6. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071-2082
7. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA (2006) Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 129:794-800
8. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ et al (2011) Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:1390-1394
9. Lee JCH, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E et al (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomised controlled trials. Lancet Respir Med 1:369-376
10. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J et al (2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27:136-142
11. Shin JM, Sachs G (2008) Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 10:528-534
12. Namazi MR, Jowkar F (2008) A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther 33:215-217
13. Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54:2312-2317
14. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W et al (2006) Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 345:1014-1021
15. Wandall JH (1992) Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 33:617-621
16. Agastya G, West BC, Callahan JM (2000) Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 22:357-372
17. Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishii H (1995) Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by helicobacter pylori. J Clin Gastroenterol 20(Suppl 2):S93-S96
18. Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H et al (1996) Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 21:727-731
19. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W (2002) Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 30:1118-1122
20. Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T et al (2006) Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res Off J Eur Histamine Res Soc 55:476-480
21. Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y et al (2000) A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14(Suppl 1):74-81
22. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH et al (2013) Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128:845-853
23. Palm F, Onozato ML, Luo Z, Wilcox CS (2007) Dimethylarginine dimethylaminohydrolase (ddah): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293:H3227-H3245
24. Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Konigshoff M et al (2011) The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci Transl Med 3:87ra53
25. Saleh D, Barnes PJ, Giaid A (1997) Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:1763-1769
26. Genovese T, Cuzzocrea S, Di Paola R, Failla M, Mazzon E, Sortino MA et al (2005) Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. Respir Res 6:58
27. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD (2010) Sparc suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem 285:8196-8206
28. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K (2011) Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev Off J Eur Respir Soc 20:85-97
29. Hultman I, Stenhoff H, Liljeblad M (2007) Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 848:317-322
30. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ats/ers/jrs/alat statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788-824
31. Eisenhart C (1947) The assumptions underlying the analysis of variance. Biometrics. 3:1-21
32. Tamhane AC, Dunlop DD(2000) Statistics and data analysis from elementary to intermediate. Prentice Hall, Upper Saddle River, NJ, pp 473-474
33. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN et al (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 103:13180-13185
34. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W et al (2009) Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 180:657-665
35. Vancheri C (2012) Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc 9:153-157
36. Mukherjee D, Coates PJ, Lorimore SA, Wright EG (2014) Responses to ionizing radiation mediated by inflammatory mechanisms. J Pathol 232:289-299
37. Hay J, Shahzeidi S, Laurent G (1991) Mechanisms of bleomycin-induced lung damage. Arch Toxicol 65:81-94
38. Bhandary YP, Shetty SK, Marudamuthu AS, Gyetko MR, Idell S, Gharaee-Kermani M et al (2012) Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiol Lung Cell Mol Physiol 302:L463-L473
39. Koli K, Myllarniemi M, Vuorinen K, Salmenkivi K, Ryynanen MJ, Kinnula VL et al (2006) Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 169:61-71
40. Myllarniemi M, Lindholm P, Ryynanen MJ, Kliment CR, Salmenkivi K, Keski-Oja J et al (2008) Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 177:321-329
41. Heron M, Van Moorsel CHM, Grutters JC, Huizinga TWJ, Van der Helm-van Mil AHM, Nagtegaal MM et al (2010) Genetic variation in grem1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens 77:112-117
42. Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F (1996) Antioxidant properties of omeprazole. FEBS Lett 382:189-192
43. Sasaki T, Nakayama K, Yasuda H, Yamaya M (2011) A new strategy with proton pump inhibitors for the prevention of acute exacerbations in copd. Ther Adv Respir Dis 5:91-103
44. Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK (2003) A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 278:10993-11001
45. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S et al (2009) Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of nf-e2-related factor 2 and oxidation of kelch-like ech-associating protein 1. J Pharmacol Exp Therap 331:255-264
46. Wang HD, Yamaya M, Okinaga S, Jia YX, Kamanaka M, Takahashi H et al (2002) Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. Am J Respir Crit Care Med 165:406-411
47. Otterbein LE, Soares MP, Yamashita K, Bach FH (2003) Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24:449-455
48. Morse D, Choi AM (2002) Heme oxygenase-1: the "emerging molecule" has arrived. Am J Respir Cell Mol Biol 27:8-16
49. Ye Q, Dalavanga Y, Poulakis N, Sixt SU, Guzman J, Costabel U (2008) Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis. Eur Respir J 31:1030-1036
50. Lakari E, Pylkas P, Pietarinen-Runtti P, Paakko P, Soini Y, Kinnula VL (2001) Expression and regulation of hemeoxygenase 1 in healthy human lung and interstitial lung disorders. Hum Pathol 32:1257-1263
51. Tsuburai T, Suzuki M, Nagashima Y, Suzuki S, Inoue S, Hasiba T et al (2002) Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cdna in lung prevents bleomycin-induced pulmonary fibrosis via a fas-fas ligand-independent pathway. Hum Gene Ther 13:1945-1960
52. Constantin M, Choi AJ, Cloonan SM, Ryter SW (2012) Therapeutic potential of heme oxygenase-1/carbon monoxide in lung disease. Int J Hypertens 2012:859235
53. Yesilkaya A, Altinayak R, Korgun DK (2000) The antioxidant effect of free bilirubin on cumene-hydroperoxide treated human leukocytes. Gen Pharmacol 35:17-20
54. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043-1046
55. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6:422-428
56. Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD, Choi AM et al (2005) Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am J Pathol 166:27-37
57. Brigham and women's hospital (2014) Study of inhaled carbon monoxide to treat idiopathic pulmonary fibrosis. Clinical Trials gov (Study Identifier:NCT01214187)
58. Zoz DF, Lawson WE, Blackwell TS (2011) Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am J Med Sci 341:435-438
59. Akram KM, Lomas NJ, Forsyth NR, Spiteri MA (2014) Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of trail, dr4 and dr5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. Int J Clin Exp Pathol 7:552-564
60. Huang S, Chen M, Ding X, Zhang X, Zou X (2013) Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting stat3 signaling pathway. Int Immunopharmacol 17:585-592
61. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM et al (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166:1321-1332
62. Kage H, Borok Z (2012) Emt and interstitial lung disease: a mysterious relationship. Curr Opin pulm Med 18:517-523
63. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M et al (2008) Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 178:838-846
64. Song R, Mahidhara RS, Liu F, Ning W, Otterbein LE, Choi AM (2002) Carbon monoxide inhibits human airway smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Am J Respir Cell Mol Biol 27:603-610
65. Tanigawa T, Watanabe T, Higuchi K, Machida H, Okazaki H, Yamagami H et al (2009) Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-alpha and interleukin-1beta induced by lipopolysaccharide and helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-kappab and extracellular signal-regulated kinase. J Clin Biochem Nutr 45:86-92
66. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M et al (2003) Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 92:226-233
67. Janssen W, Pullamsetti SS, Cooke J, Weissmann N, Guenther A, Schermuly RT (2013) The role of dimethylarginine dimethylaminohydrolase (ddah) in pulmonary fibrosis. J Pathol 229:242-249
68. Trifilieff A, Fujitani Y, Mentz F, Dugas B, Fuentes M, Bertrand C (2000) Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression. J Immunol 165:1526-1533
69. Batra J, Chatterjee R, Ghosh B (2007) Inducible nitric oxide synthase (inos): role in asthma pathogenesis. Indian J Biochem Biophys 44:303-309
70. Linden PA, Gilbert RJ, Yeap BY, Boyle K, Deykin A, Jaklitsch MT et al (2006) Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 131:438-446
71. Behera D, Kaur S, Sathyanarayana G, Bhatnagar A, Majumdar S (2002) Nitric oxide derivative in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Indian J Chest Dis Allied Sci 44:21-24
72. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424
73. Teabeaut JR 2nd (1952) Aspiration of gastric contents; an experimental study. Am J Pathol 28:51-67
74. Greenfield LJ, Singleton RP, McCaffree DR, Coalson JJ (1969) Pulmonary effects of experimental graded aspiration of hydrochloric acid. Ann Surg 170:74-86
75. El-Serag HB, Sonnenberg A (1997) Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in united states military veterans. Gastroenterology 113:755-760
76. Mays EE, Dubois JJ, Hamilton GB (1976) Pulmonary fibrosis associated with tracheobronchial aspiration. A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 69:512-515
77. Salvioli B, Belmonte G, Stanghellini V, Baldi E, Fasano L, Pacilli AM et al (2006) Gastro-oesophageal reflux and interstitial lung disease. Dig Liver Dis 38:879-884
78. Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C et al (2007) Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 133:1078-1084
79. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM et al (2010) Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 123:304-311
80. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G (1998) Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1804-1808
81. Locke GR 3rd (2005) Current medical management of gastroesophageal reflux disease. Thorac Surg Clin 15:369-375
82. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810-816
83. Katzenstein AL, Myers JL (1998) Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 157:1301-1315
84. Trahan S, Hanak V, Ryu JH, Myers JL (2008) Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia/idiopathic pulmonary fibrosis: analysis of 31 biopsies from 15 patients. Chest 134:126-132
85. Gribbin J, Hubbard R, Smith C (2009) Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 103:927-931
86. Bandeira CD, Rubin AS, Cardoso PF, Moreira Jda S, Machado Mda M (2009) Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 35:1182-1189
87. Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A, Damani T et al (2005) Idiopathic pulmonary fibrosis: How often is it really idiopathic? J Gastrointest Surg. 9:1053-1056 discussion 1056-1058
88. Troshinsky MB, Kane GC, Varga J, Cater JR, Fish JE, Jimenez SA et al (1994) Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 121:6-10
89. Raghu G (2011) Idiopathic pulmonary fibrosis: increased survival with "gastroesophageal reflux therapy": fact or fallacy? Am J Respir Crit Care Med 184:1330-1332
90. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A et al (2002) Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 99:6292-6297
91. Ruhrmund DWLS, Qin X, Arfsten AE, Hooi L, Kartashov A, Weycker D et al (2014) Matrix metalloproteinase (mmp)-7 predicts mortality in idiopathic pulmonary fibrosis (ipf). Am J Respir Crit Care Med 189:A3924
92. Zhou Y, Peng H, Sun H, Peng X, Tang C, Gan Y et al (2014) Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis. Sci Transl Med. 6:240ra276
93. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J (2001) Transient expression of il-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107:1529-1536
94. Sullivan DE, Ferris M, Pociask D, Brody AR (2008) The latent form of tgfbeta(1) is induced by tnfalpha through an erk specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo. J Immunotoxicol 5:145-149
95. Farre R, Sifrim D (2008) Regulation of basal tone, relaxation and contraction of the lower oesophageal sphincter. Relevance to drug discovery for oesophageal disorders. Br J Pharmacol 153:858-869
96. Damsch S, Eichenbaum G, Tonelli A, Lammens L, Van den Bulck K, Feyen B et al (2011) Gavage-related reflux in rats: identification, pathogenesis, and toxicological implications (review). Toxicol Pathol 39:348-360
97. Hu YR, Qiao HL, Kan QC (2004) Pharmacokinetics of lansoprazole in chinese healthy subjects in relation to cyp2c19 genotypes. Acta Pharmacol Sin 25:986-990
98. Howden CW (1991) Clinical pharmacology of omeprazole. Clin Pharmacokinet 20:38-49